Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study

Abstract Background The burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery em...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rachel K. Lim, Alain Tremblay, Shengjie Lu, Ranjani Somayaji
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/50581feff1364b928b5ec6550e804f69
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:50581feff1364b928b5ec6550e804f69
record_format	dspace
spelling	oai:doaj.org-article:50581feff1364b928b5ec6550e804f692021-12-05T12:23:24ZEvaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study10.1186/s12890-021-01762-61471-2466https://doaj.org/article/50581feff1364b928b5ec6550e804f692021-12-01T00:00:00Zhttps://doi.org/10.1186/s12890-021-01762-6https://doaj.org/toc/1471-2466Abstract Background The burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery embolization, length of stay, and hospitalization costs. Methods The authors queried the Nationwide Inpatient Sample (NIS) claims database for hospitalizations between 2016 and 2017 using the ICD-10-CM codes for hemoptysis and bronchiectasis in the United States. Multivariable regression was used to evaluate predictors of in-hospital mortality, embolization, length of stay, and hospital costs. Results There were 8240 hospitalizations (weighted) for hemoptysis in the United States from 2016 to 2017. The overall in-hospital mortality was 4.5%, but higher in males compared to females. Predictors of in-hospital mortality included undergoing three or more procedures, age, and congestive heart failure. Bronchial artery embolization (BAE) was utilized during 2.1% of hospitalizations and was more frequently used in those with nontuberculous mycobacteria and aspergillus infections, but not pseudomonal infections. The mean length of stay was 6 days and the median hospitalization cost per patient was USD $9,610. Having comorbidities and procedures was significantly associated with increased length of stay and costs. Conclusion Hemoptysis is a frequent indication for hospitalization among the bronchiectasis population. In-hospital death occurred in approximately 4.5% of hospitalizations. The effectiveness of BAE in treating and preventing recurrent hemoptysis from bronchiectasis needs to be explored.Rachel K. LimAlain TremblayShengjie LuRanjani SomayajiBMCarticleDiseases of the respiratory systemRC705-779ENBMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the respiratory system RC705-779
spellingShingle	Diseases of the respiratory system RC705-779 Rachel K. Lim Alain Tremblay Shengjie Lu Ranjani Somayaji Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
description	Abstract Background The burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery embolization, length of stay, and hospitalization costs. Methods The authors queried the Nationwide Inpatient Sample (NIS) claims database for hospitalizations between 2016 and 2017 using the ICD-10-CM codes for hemoptysis and bronchiectasis in the United States. Multivariable regression was used to evaluate predictors of in-hospital mortality, embolization, length of stay, and hospital costs. Results There were 8240 hospitalizations (weighted) for hemoptysis in the United States from 2016 to 2017. The overall in-hospital mortality was 4.5%, but higher in males compared to females. Predictors of in-hospital mortality included undergoing three or more procedures, age, and congestive heart failure. Bronchial artery embolization (BAE) was utilized during 2.1% of hospitalizations and was more frequently used in those with nontuberculous mycobacteria and aspergillus infections, but not pseudomonal infections. The mean length of stay was 6 days and the median hospitalization cost per patient was USD $9,610. Having comorbidities and procedures was significantly associated with increased length of stay and costs. Conclusion Hemoptysis is a frequent indication for hospitalization among the bronchiectasis population. In-hospital death occurred in approximately 4.5% of hospitalizations. The effectiveness of BAE in treating and preventing recurrent hemoptysis from bronchiectasis needs to be explored.
format	article
author	Rachel K. Lim Alain Tremblay Shengjie Lu Ranjani Somayaji
author_facet	Rachel K. Lim Alain Tremblay Shengjie Lu Ranjani Somayaji
author_sort	Rachel K. Lim
title	Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
title_short	Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
title_full	Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
title_fullStr	Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
title_full_unstemmed	Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
title_sort	evaluating hemoptysis hospitalizations among patients with bronchiectasis in the united states: a population-based cohort study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/50581feff1364b928b5ec6550e804f69
work_keys_str_mv	AT rachelklim evaluatinghemoptysishospitalizationsamongpatientswithbronchiectasisintheunitedstatesapopulationbasedcohortstudy AT alaintremblay evaluatinghemoptysishospitalizationsamongpatientswithbronchiectasisintheunitedstatesapopulationbasedcohortstudy AT shengjielu evaluatinghemoptysishospitalizationsamongpatientswithbronchiectasisintheunitedstatesapopulationbasedcohortstudy AT ranjanisomayaji evaluatinghemoptysishospitalizationsamongpatientswithbronchiectasisintheunitedstatesapopulationbasedcohortstudy
_version_	1718371955922436096

Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study

Ejemplares similares